Please find enclosed the disclosure under Regulation 30 of SEBI LODR Regulations regarding Earnings Presentation for Q1 FY 27

Ref No.: ZLL/CS/BSE/NSE Date: 06.08.2026 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) Dear Sir/Madam, Sub: Q1 FY27 - Earnings Presentation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed Q1 FY27 - Earnings Presentation. Kindly take the intimation on record. Thanking you, Yours faithfully, For ZIM LABORATORIES LIMITED (Piyush Nikhade) Company Secretary and Compliance Officer Membership No. A38972 Encl: As above. ZIM LABORATORIES LIMITED www.zimlab.in I info@zimlab.in I CIN : L99999MH1984PLC032172 Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Maharashtra, India. Ph. + 91.718.271370 I Fax : +091.7118.271470 Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960 ZIM LABORATORIES LIMITED Zeal & Innovation in Medicine EAR NI NG S P RES ENT A TI ON Q1 FY27 Innovation www.zimlab.in Quality People SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited ("ZIM" or the "Company") solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. By accessing this presentation, you are agreeing to be bound by the trading restrictions. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its affiliates, advisors or representatives are under an obligation to update, revise or affirm. Certain statements contained in this presentation may be statements of the Company's beliefs, plans and expectations about the future and other forward-looking statements. The forward-looking statements are based on management's current expectations or beliefs as well as a number of assumptions about the Company's operations and facto beyond the Company's control or third-party sources and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. There is no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward looking statements, which speak only as of the date of this presentation. The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. You acknowledge and agree that the Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed. ZiM Laboratories Limited · For Information Purposes Only · Not an Offer to Buy or Sell Securities Table of Content Q1 FY27 Highlights Financial performance snapshot for the quarter 02 Financial Performance Q1 FY27 Revenue, EBITDA, margins and R&D investment trends 03 Business Mix Product and market mix driving the revenue profile 04 R&D & Innovation NIP & OTF pipeline progress, approvals and investment Shareholding Ownership structure and trading volumes - BSE + NSE Q1 FY27 FINANCIAL HIGHLIGHTS Q1 FY27 Vs Q1 FY26 Total Operating Income ₹942 Mn ₹718 Mn ▲ 31.2% EBITDA ₹34 Mn ₹57 Mn ▼ 40.0% EBITDA Margin 3.7% 7.9% ▼ 430 bps Total R&D Spend* ₹82 Mn 8.7% of TOI *Incl. ₹34 Mn towards BE studies & regulatory filings REGULATORY MOMENTUM (Q1 FY27) Filings & Approvals FILED WITH MOH MAs RECEIVED FROM MOH NIP ODS FF NIP ODS FF 2 9 6 4 3 3 New Innovative Oral Thin Finished Formulations New Innovative Oral Thin Finished Formulations Products Films Generic Products Films Generic 17 10 3 NIP · ODS · FF Generic for the Developed, Pharmerging & RoW Markets Total Filings MAs Received Filing Types STATUS UPDATE & PROGRESS ON EU-GMP CAPA REMEDIATION Most of the CAPA remediation plan has been completed and implemented Q2 FY26 June / July EU GMP Inspection. Onboarding External Consultant for CAPA Plan. Submission 01 Q2 FY26 Complete of comprehensive CAPA Remediation Plan. Capital Expenditure Orders placed for key systems needed. Contract Manufacturing for alternate site with accreditations finalised for Star Product 1. Q3 FY26 02 Submission of CAPA Progress for upto October 2026. Appointment of European Consultant Q3 FY26 Complete for CAPA Remediation. Strengthening Team in QMS. Training of Team. Additional CMO for specific markets being finalized. Hiring of QA Head. Q4 FY26 Independent assessment by European + Indian Consultant. Effectiveness check on CAPA 03 Q4 FY26 Complete remediation progress . Validation by Consultants . Submission of CAPA Progress.. Initiatives on triggering Audits from other regions. Filing Batches from CMO Partners for Star Product 1. Pre-Audit by External Consultants.. Potential Re-Audit of facility by EMA inspectors. Q1 FY27 04 Registration of Products in Pharmerging & RoW Markets. Feedback on other Audits : Re- Q1 FY27 Complete Audit of facility by EMA inspectors. Launch of Star Product 1 in Alternate Markets. Extend alternate manufacturing strategy to other markets. Q2 FY27 05 CAPA Submission planned after receipt of final report from EMA inspectors. Secure order for Q2 FY27 In Progress Star Product 1 in other developed markets. Start planning for supplies to EU and UK markets by planning for Raw Material availability and production readiness In addition to this, we underwent TGA Audit and PIC/S Malaysia audit TOTAL OPERATING INCOME Total Operating Income (₹Mn) 1,087 1,053 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 ₹ Mn • Total Operating Income at ₹942 Mn, up 31.2% YoY • Total Operating Income down 10.5% QoQ due to war situation in the Mid East and serious logistic challenges; some early signs of improvement EBITDA & EBITDA % EBITDA & EBITDA Margin 13.4% 12.7% 8.8% ig 7.9% a ₹ 145 134 T 3.7% Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 EBITDA EBITDA Margin • EBITDA at ₹34 Mn, down 40% YoY; EBITDA margins at 3.7% vs 7.9% in Q1 FY26. • Gross contribution margins remained in line with margins for the year FY26 and the previous quarter • Lower EBITDA margins primarily due to increased utility and [Showing first 8,000 characters — download PDF for full document]